HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NUVB
Nuvation Bio Inc.
There isn't enough reported data to score NUVB yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NUVB Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Unavailable | |
| Unavailable |
NUVB's revenue is currently healthy, but its profitability is weak. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NUVB PE Valuation
NUVB has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NUVB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
NUVB has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over NUVB in the latest year-over-year earnings comparison.
NUVB Earnings Per Share
NUVB lost $0.49 per share over the past year, a bigger loss than the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over NUVB on profitability, with a higher operating margin.
NUVB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $45M | +243% |
| Q2 2026 | $31.7M | +556% |
| Q1 2026 | $83.2M | +2599% |
| Q4 2025 | $41.9M | +633% |
| Q3 2025 | $13.1M | +1705% |
| Q2 2025 | $4.8M | +237% |
NUVB has the edge over HIMS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -94% | +336 points |
| Q2 2026 | -161% | +1155 points |
| Q1 2026 | 4.7% | +1918 points |
| Q4 2025 | -81% | +863 points |
| Q3 2025 | -430% | +6186 points |
| Q2 2025 | -1316% | +31464 points |
| Q1 2025 | -1913% | N/A |
| Q4 2024 | -945% | N/A |
NUVB's operating margin was −94% last quarter, up 336 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
NUVB has the stronger cash trend. Its trailing FCF is down 23% versus its history, compared with HIMS at down 84%.
NUVB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$43M | +$5.2M |
| Q1 2026 | $5.1M | +$47.7M |
| Q4 2025 | -$29.7M | +$16.6M |
| Q2 2025 | -$48.2M | -$10.9M |
| Q1 2025 | -$42.6M | -$26.9M |
| Q4 2024 | -$46.3M | -$31.3M |
| Q3 2024 | -$31.1M | -$14.9M |
| Q2 2024 | -$37.3M | -$19.8M |
NUVB has burned cash in almost every quarter: −$116M over the past year, against −$157M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NUVB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -8.3% | -19.7M shares |
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NUVB Net Leverage
NUVB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NUVB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.3 | Neutral |
| Stochastic | 6.8 | Oversold |
NUVB's weekly RSI is 35 (neutral) and its Stochastic is 7 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NUVB PE vs Healthcare Sector
NUVB has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NUVB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.74 | 14% below |
| 20 week MA | $5.65 | 28% below |
| 50 week MA | $5.71 | 29% below |
| 100 week MA | $4.29 | 5.4% below |
| 200 week MA | $3.22 | 26% above |
NUVB has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over NUVB on returns for 2026, with the stronger performance.
NUVB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.95 | $10.6 | +6.4% |
| 2021 | $10.6 | $8.23 | -22% |
| 2022 | $8.23 | $1.77 | -78% |
| 2023 | $1.77 | $1.51 | -15% |
| 2024 | $1.51 | $2.76 | +83% |
| 2025 | $2.76 | $9.40 | +241% |
| 2026 YTD | $9.40 | $4.06 | -57% |
NUVB's yearly returns have swung widely, from +241% in 2025 to −78% in 2022. It's down 57% so far in 2026.